Drugplain

bromfenac 1.035 mg/mL

bromfenac · SOLUTION/ DROPS · Alembic Pharmaceuticals Limited

No Recall History
Plain English

bromfenac is a solution/ drops containing bromfenac at 1.035 mg/mL, taken ophthalmic. Manufactured by Alembic Pharmaceuticals Limited.

Key Facts

Brand Name
bromfenac
Generic Name
bromfenac
NDC Code (Product)
46708-508
Manufacturer
Alembic Pharmaceuticals Limited
Strength
1.035 mg/mL
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC
Marketing Status
Application #
ANDA210560
Marketing Start
11/10/2022

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

treatment failure146 reports
drug ineffective63 reports
eye pain43 reports
fatigue31 reports
cataract28 reports
visual impairment27 reports
endophthalmitis26 reports
eye irritation26 reports
off label use26 reports
product dose omission issue24 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

1 INDICATIONS AND USAGE Bromfenac Ophthalmic Solution 0.09% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction (1) .

Dosage & Administration

2 DOSAGE AND ADMINISTRATION Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery and through the first 14 days post-surgery (2.1) . 2.1 Recommended Dosing For the treatment of postoperative inflammation in patients who have undergone cataract extraction, one drop of bromfenac ophthalmic solution should be applied to the affected eye once daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the postoperative period. 2.2 Use with Other Topical Ophthalmic Medications Bromfenac ophthalmic solution may be administered in conjunction with other topical ophthalmic medications such as alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.

Contraindications

4 CONTRAINDICATIONS None.

Adverse Reactions

6 ADVERSE REACTIONS The most commonly reported adverse reactions in 2-7% of patients were abnormal sensation in eye, conjunctival hyperemia and eye irritation (including burning/stinging) (6.1) . To report SUSPECTED ADVERSE REACTIONS, contact Sentiss at 1-855-473-6847 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trial Experience The most commonly reported adverse experiences reported following use of bromfenac after cataract surgery include: abnormal sensation in eye, conjunctival hyperemia, eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, headache, and iritis. These events were reported in 2-7% of patients. 6.2 Post-Marketing Experience The following events have been identified during post-marketing use of bromfenac ophthalmic solution 0.09% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical bromfenac ophthalmic solution 0.09% or a combination of these factors, include corneal erosion, corneal perforation, co

Frequently Asked Questions

What is bromfenac used for?

bromfenac contains bromfenac. It is a solution/ drops taken ophthalmic. Consult your doctor for specific uses.

Is bromfenac a controlled substance?

bromfenac is not classified as a controlled substance by the DEA.

What is the generic name for bromfenac?

The generic name for bromfenac is bromfenac. There are 11 other brand versions of bromfenac.

What is the NDC code for bromfenac 1.035 mg/mL?

The NDC (National Drug Code) for bromfenac 1.035 mg/mL is 46708-508, listed by Alembic Pharmaceuticals Limited.